Overview

• Middle-aged adults (41–56) in the Young Finns Study showed detectable blood-based Alzheimer’s biomarkers that increased with age.
• Offspring whose mothers had high biomarker concentrations exhibited correspondingly elevated midlife levels.
• Participants with chronic kidney disease had independently higher Alzheimer’s biomarker readings by middle age.
• APOE ε4 carriers did not show significant midlife biomarker increases despite its known risk association later in life.
• Researchers emphasize that defining reference values and validating assays across varied cohorts is essential before clinical adoption.